

TO THE SPANISH SECURITIES COMMISSION

Fluidra, S.A. ("**Fluidra**" or the "**Company**"), pursuant to the provisions of section 227 of the Spanish Securities Markets and Investment Services Act, approved by Law 6/2023, of 17 March, hereby issues the following:

OTHER RELEVANT INFORMATION

The Ordinary General Shareholders' Meeting of Fluidra held today 6 May 2026, has approved each and every one of the items included on the Agenda, which was notified by means of a Communication of Other Relevant Information on 26 March 2026, under registration number 39920 and which is transcribed hereunder:

Item One: **Approval of the annual financial statements and of the management report, both of the Company and of its consolidated group of companies, for the fiscal year ended December 31, 2025.**

Approved resolution

To approve the annual financial statements of the Company, consisting of the balance sheet, the income statement, the statement of changes in equity, the statement of cash flows and the notes to the financial statements, and the management report, of Fluidra, S.A. and of its consolidated group of companies, for the fiscal year ended December 31, 2025, prepared by the Board of Directors of Fluidra, S.A. on March 24, 2026.

Item Two: **Approval of the consolidated statement of non-financial information and sustainability information of Fluidra, S.A. for the fiscal year ended December 31, 2025.**

Approved resolution

To approve the consolidated statement of non-financial information and sustainability information for the fiscal year ended December 31, 2025, included in the consolidated management report of Fluidra, S.A.

Item Three: **Approval of the proposed allocation of income/loss for the fiscal year ended December 31, 2025.**

Approved resolution

FLUIDRA

To approve the proposed allocation of income/loss for the fiscal year of Fluidra, S.A. ended on December 31, 2025, in accordance with the following distribution:

Total income to be distributed:	167,306,535.63 euros
- To the payment of a dividend	123,429,082.40 euros ¹
- To voluntary reserves:	43,877,453.23 euros ²

The dividend shall be paid in cash, in the gross amount of 0.65 euros per share of the Company entitled to receive it, representing a maximum total dividend of 124,883,895.50 euros if the distribution were made in relation to all of the Company's ordinary shares (considering that the Company's share capital on the date of this resolution is divided into a total of 192,129,070 shares with a par value of 1 euro each), i.e., if there were no treasury shares.

The dividend will be paid in two payments, on each payment date and for the gross amounts per share indicated below, through the member entities of Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores (IBERCLEAR):

- First payment – July 14, 2026: maximum total amount to be distributed of 0.32 euros gross per share of the Company entitled to receive it.
- Second payment – December 10, 2026: maximum total amount to be distributed of 0.33 euros gross per share of the Company entitled to receive it.

Withholding taxes will be deducted from the gross amounts paid, in accordance with applicable law at any given time. Should the share capital of the Company and/or the number of shares into which it is divided be modified, the gross amount per share on each payment date will be adjusted accordingly. In any case, the maximum total amount to be distributed on each payment date may not exceed the amounts indicated above (i.e., the maximum amount of €61,481,302.40 on the first payment date and €63,402,593.10 on the second payment date).

To authorize the Board of Directors, in the broadest terms, with the express power of delegation, to adopt all decisions and take all the steps necessary or advisable for the payment of the previously approved dividend, including, in particular and without limitation, setting the terms and conditions of the distribution in all matters not previously provided for (including determining the exact dates on which the registered holders entitled to receive the dividend will be determined), designating the entity or entities that will act as paying agents and signing the corresponding contracts under the terms and conditions it deems

¹ Estimated amount related to the payment of a dividend of 0.65 euros per share, to be paid in cash. The amount of 123,429,082.40 euros has been calculated assuming treasury stock equal to that existing on the last day of the fiscal year ended on December 31, 2025 (2,238,174 treasury shares). Therefore, the total dividends will be decreased or increased based on the number of treasury shares at the Company when the dividend is paid, given that, according to the Capital Companies Law, treasury stock may not receive dividends.

² This amount will be increased or decreased by the same amount as the amount allocated to the dividend payment (see note (1) above).

appropriate, making use of demand deposit accounts for the purpose, serving the appropriate communications and notifications and, in general, taking any other step necessary or advisable for the successful completion of the approved distribution.

Item Four: Approval of the management carried out by the Board of Directors during the fiscal year 2025.

Approved resolution

To approve the management carried out by the Board of Directors of Fluidra, S.A. during the fiscal year 2025.

Item Five: Re-election of Mr. José Manuel Vargas Gómez as proprietary Director of the Company.

The Shareholders' Meeting is first informed of the vacancy that arose on the Board of Directors due to the expiration of the term of office of the proprietary director Mr. José Manuel Vargas Gómez on May 5, 2026. Piscine Luxembourg Holdings 1 S.à r.l., whose interests were represented by Mr. Vargas, proposes to this Shareholders' Meeting his re-election as a director in the category of proprietary director.

Approved resolution

To re-elect Mr. José Manuel Vargas Gómez, following the proposal by the Appointments and Compensation Committee, as a member of the Board of Directors of Fluidra, S.A., for a term of two (2) years, with the category of proprietary director.

In compliance with sections 4, 5 and 6 of article 529 decies of the Spanish Capital Companies Law, approved by Legislative Royal Decree 1/2010, of July 2, 2010, it is placed on record that: (i) the Board of Directors proposed the reelection of Mr. José Manuel Vargas Gómez at its meeting held on March 24, 2026; (ii) this proposed reelection was supported by the required report assessing the suitability of Mr. José Manuel Vargas Gómez, issued by the Board of Directors on March 24, 2026 and attached to the minutes of the Board of Directors' meeting; and (ii) the proposal to reelect Mr. José Manuel Vargas Gómez was preceded by a favorable report issued by the Company's Appointments and Compensation Committee at its meeting of March 23, 2026 and attached to the minutes of the Appointments and Compensation Committee meeting.

Item Six: Ratification of the appointment by co-option and appointment of Ms. M. Allison Steiner as a proprietary Director of the Company.

The Shareholders' Meeting is first informed of the vacancy that arose on the Board of Directors as a result of the resignation tendered, with effects from February 22, 2026, by Mr. M. Steven Langman, from the position of proprietary director of the Company, representing the shareholder interests of Piscine Luxembourg Holdings 1 S.à r.l. In order to fill the vacancy that arose on the Company's Board of Directors, at the proposal of

shareholder Piscine Luxembourg Holdings 1 S.à r.l., the Board of Directors appointed Ms. Allison Steiner as a proprietary director of the Company by the co-option procedure. Piscine Luxembourg Holdings 1 S.à r.l., whose interests were represented by Mr. Langman, proposes to this Shareholders' Meeting the ratification and appointment of Ms. M. Allison Steiner as a director with the category of proprietary director.

Approved resolution

To ratify and appoint Ms. M. Allison Steiner, following the favorable report issued by the Appointments and Compensation Committee, as a member of the Board of Directors of Fluidra, S.A., for a term of two (2) years, with the category of nominee director.

In accordance with sections 1, 4, 5 and 6 of article 529 decies of the Spanish Capital Companies Law, approved by Legislative Royal Decree 1/2010, of July 2, 2010, it is placed on record that: (i) the Board of Directors has approved the appointment by co-option of Ms. M. Allison Steiner at its meeting held on February 24, 2026, conditional on its subsequent ratification by the first Shareholders' Meeting of the Company to be held; (ii) that appointment and the proposal for ratification and appointment submitted to the Shareholders' Meeting was supported by the required report assessing the suitability of Ms. M. Allison Steiner and was issued by the Board of Directors on February 24, 2026 and attached to the minutes of the Board of Directors' meeting; and (ii) the proposal to appoint Ms. M. Allison Steiner was preceded by a favorable report issued by the Company's Appointments and Compensation Committee at its meeting of February 23, 2026 and attached to the minutes of the Appointments and Compensation Committee meeting.

Item Seven: Appointment of Mr. Stephen G. Kaniewski as independent Director of the Company.

The Shareholders' Meeting is first informed of the vacancy that arose on the Board of Directors due to the expiration of the term of office of the independent director Ms. Bárbara Borra on May 5, 2026.

Approved resolution

To appoint Mr. Stephen G. Kaniewski, following the favorable report issued by the Appointments and Compensation Committee, as a member of the Board of Directors of Fluidra, S.A., for a term of two (2) years, with the category of independent director.

In accordance with sections 1, 4, 5 and 6 of article 529 decies of the Spanish Capital Companies Law, approved by Legislative Royal Decree 1/2010, of July 2, 2010, it is placed on record that: (i) the Board of Directors proposed the appointment of Mr. Stephen G. Kaniewski at its meeting held on March 24, 2026; (ii) this proposed appointment was supported by the required report assessing the suitability of Mr. Stephen G. Kaniewski, issued by the Board of Directors on March 24, 2026 and attached to the minutes of the Board of Directors' meeting; and (ii) the proposal to appoint Mr. Stephen G. Kaniewski was preceded by the proposal made by the Company's Appointments and Compensation Committee at its meeting of March 23, 2026, which issued a favorable report attached to the minutes of said meeting of the Appointments and Compensation Committee.

Item Eight: **Consultative vote on the annual report on directors' compensation for fiscal year 2025.**

Approved resolution

To vote in favor of the Annual Report on Director Compensation, which includes information on Fluidra, S.A.'s compensation policy for the current year, the policy foreseen for future years, an overall summary of how the compensation policy was applied during the 2025 fiscal year and a breakdown of individual remuneration accrued by each of the directors, submitted to this shareholders' meeting for consultation.

Item Nine: **Authorization to the Board of Directors, during a 5-year period, to increase share capital in the terms and with the limits established by law, with the authority to exclude shareholders' pre-emptive subscription rights limited to an overall maximum of 10% of share capital.**

Approved resolution

To delegate to the Board of Directors of Fluidra S.A., the power, as broad as required by law, to increase the Company's share capital, subject to the bylaw and statutory provisions applicable at any time, within the statutory period of five (5) years from the date on which this resolution is approved, up to half of the current share capital.

To also empower the Board of Directors of Fluidra, S.A., as broadly as required by law, so that, as it deems most advisable, it can:

- (i) Resolve to increase the share capital of Fluidra, S.A. on one or more occasions, in the amount and at the time so decided by the Board of Directors, within the limits established in this resolution, by issuing new voting or non-voting shares, whether common or preference, including redeemable shares or shares of any other type permitted by law, with or without share premium; with the consideration being monetary contributions; and with the power to establish the terms and conditions of the capital increase in all aspects not envisaged in this resolution, including determining the par value of the shares to be issued, their features and any privileges they may confer on their owners, such as, where appropriate, the allocation of the redemption right as part of their conditions and the exercise thereof by the Company.
- (ii) Freely offer the shares that have not been subscribed in the period established for the exercise of the pre-emptive subscription right, where granted; establish that, in the case of incomplete subscription, the share capital will be rendered ineffective pursuant to article 507 of the Capital Companies Law; and amend the corresponding Articles of Association article accordingly.
- (iii) Request, as the case may be, the listing of any shares issued under this delegation on Spanish or foreign official or unofficial secondary markets, whether regulated or

not, and take any action or measures necessary or advisable to that end before the corresponding public and/or private bodies, including any actions, statements or formalities before the competent authorities.

It is expressly placed on record that the Company is subject to the existing market rules and any that may be issued and, in particular, with respect to the trading, continued listing, and delisting of shares, as well as its commitment that, if the delisting of the shares is subsequently requested, it will be adopted with the formalities required by the applicable legislation.

- (iv) In accordance with the provisions of the Capital Companies Law, exclude, in part or in full, the pre-emptive subscription rights of shareholders in connection with any specific share issue made by virtue of this resolution, where this is in the corporate interest and fulfilling the statutory requirements established in that regard.

Nevertheless, without prejudice to compliance with any other legal limits established in that regard at any time, the power to exclude pre-emptive subscription rights shall be limited as follows: the nominal amount of the capital increases approved or effectively carried out excluding the pre-emptive subscription rights by virtue of this delegation, and those that may be resolved or executed as part of the conversion of any convertible issues that may also be made excluding the pre-emptive subscription right by virtue of the delegation given in item ten, below, on the agenda for this Shareholders' Meeting (without prejudice to any anti-dilution adjustments), may not exceed the overall maximum nominal amount of ten percent (10%) of the Company's share capital at the time of this delegation.

To empower the Board of Directors, in the broadest terms, to exercise the delegation made in this resolution, as well as to perform all acts, procedural formalities and requests as may be necessary or advisable for the exercise thereof, authorizing the Board to subdelegate to the Executive Chairman of the Board of Directors, to the Chief Executive Officer or to any other director, and to empower, with the scope deemed necessary, any attorney-in-fact of the Company for its execution.

From the moment of its approval, this authorization supersedes and cancels the authorization granted by the Company's Annual Shareholders' Meeting held on May 5, 2022, under agenda item sixteen.

Item Ten:

Authorization to the Board of Directors, for a term of 5 years, to issue debentures exchangeable for and/or convertible into shares and warrants in an amount up to €500,000,000, with the power to exclude the shareholders' pre-emptive subscription rights limited to an overall maximum of 10% of the share capital.

Approved resolution

FLUIDRA

To authorize the Board of Directors, pursuant to the general regime on debenture issues and pursuant to articles 286, 297 and 511 of the Capital Companies Law and 319 of the Commercial Registry Regulations, to issue securities pursuant to the following terms:

(i) Securities issued

The securities referred to in this authorization are all manner of securities (including, in particular, debentures, bonds and warrants) exchangeable for or with the right to acquire outstanding shares of the Company or other group companies, and/or convertible into or with the right to subscribe new shares of the Company.

(ii) Duration of the delegation

The securities may be issued, on one or more occasions, at any time, within a maximum time-period of five (5) years from the date of adoption of this resolution.

(iii) Maximum amount of the authorization

The total maximum nominal amount of the securities issue(s) that are agreed pursuant to this delegation shall be five hundred million euros (€500,000,000) or the equivalent amount in any other currency. For the purposes of calculating the above limit, in the case of warrants, the sum of the premiums and exercise prices of the issues resolved upon under this authorization shall be taken into account.

(iv) Scope of the authorization

This authorization extends, as broadly as required in law, to the establishment of the different terms and conditions of each issue, including but not limited to the following:

- a. the amount, always within the total quantitative limits indicated above;
- b. the place of issue (Spain or other country) and the type of issue;
- c. the currency (domestic or foreign) and, in the case of foreign currency, the equivalent in euros (€);
- d. the denomination or form of the securities, whether they are bonds and debentures, including subordinated debentures, warrants (which may in turn may be settled by physical delivery of shares or, where applicable, by offsetting), or any other denomination or form permitted by law;
- e. the issue date(s);
- f. the number of securities and their par value which, in the case of bonds or convertible and/or exchangeable debentures, may not be less than the par value of the shares;

- g. in the case of warrants and other similar securities, the issue and/or premium price, the exercise price (which may be fixed or variable) and the procedure, time-period, and other terms and conditions applicable to the exercise of the right to subscribe the underlying shares or, where applicable, the exclusion of said right; the interest rate (fixed or variable), and the dates and procedures to pay the coupon; whether the issue is perpetual or subject to redemption and, in this latter case, the redemption period and the maturity date(s);
- h. the guarantees, repurchase price and rights, premiums and lots;
- i. the type of representation, such as securities or book entries;
- j. anti-dilution clauses;
- k. the placement and subscription system and the rules applicable to subscription;
- l. the ranking of securities and subordination clauses, where applicable; legislation applicable to the issue;
- m. the power to request the admission to trading, where applicable, of the securities issued in secondary markets, organized or unorganized, official or unofficial, Spanish or foreign, subject to the requirements established by applicable legislation in each case; and
- n. in general, any other condition of issue, and, as the case may be, the appointment of the trustee of the syndicate of holders of securities and the approval of the basic rules that will govern legal relations between the Company and the syndicate of holders of the securities issued, in the event that it is necessary to create or it is decided to create said syndicate.

The authorization also includes the conferral on the Board of Directors of the power to decide, in each case, on the conditions for redemption of the securities issued under this authorization, being able to use, to the extent applicable, the means of redemption referred to in article 430 of the Capital Companies Law or any others that may be applicable.

The Board of Directors is also empowered so that, where it sees fit, and subject to the obtainment of the necessary official authorization and, as the case may be, approval from the Assemblies of the corresponding syndicates or bodies representing the holders of the securities, it may modify the conditions of the securities issued and their respective time periods and the rate of any interest

accruing on the securities included in each of the issues made under this authorization.

(v) Basis and methods of conversion and/or exchange

In the case of issues of convertible and/or exchangeable securities (including debentures or bonds), and in order to determine the basis and methods of conversion and/or exchange, the following criteria are established:

- a. the securities issued in accordance with this resolution shall be exchangeable for shares of the Company or any other company, whether or not it belongs to its group and/or convertible into newly issued shares of the Company, in accordance with a fixed or variable, determined or determinable conversion or exchange ratio, the Board of Directors having the power to determine whether they are convertible and/or exchangeable, and to determine whether they are necessarily or voluntarily convertible or exchangeable and, where voluntary, whether it is at the election of their holder and/or the Company, with the frequency and during the time period established in the issue resolution;
- b. the Board of Directors may also establish in the event that the issue is convertible and exchangeable, that the issuer reserves the right to choose at any time between the conversion into new shares or the exchange for existing shares, specifying the nature of the shares to be delivered upon conversion or exchange, and may even choose to deliver a combination of new and preexisting shares of the Company, and even to settle the difference in cash;
- c. for the purposes of the conversion and/or exchange, the securities shall be valued at their nominal amount (including, where applicable, outstanding interest accrued) and the shares at the fixed exchange rate established in the resolution by the Board of Directors in which this authorization is used, or at the variable exchange rate to be determined on the date or dates indicated in the resolution itself, in accordance with the market value of the Company shares on the date(s) or in the period(s) established as a reference in the resolution itself, with a premium or, as the case may be, a discount, although if a discount on the price per share is established it may not be higher than twenty-five percent (25%) of the value of the shares taken as a reference pursuant to the above;
- d. the value of the shares for the purposes of the conversion of debentures into shares may not, under any circumstances, be less than the nominal value of the shares. Similarly, pursuant to article 415 of the Capital Companies Law, debentures that are convertible into shares may not be issued either, where their nominal value is less than that of the shares.

(vi) Basis and methods of exercising the warrants and other similar securities

In relation to issues of warrants, to which the Capital Companies Law on convertible debentures is applicable by analogy, the Board of Directors is authorized to

determine, on its broadest terms, the basis and terms and conditions applicable to the exercise of the warrants, the criteria applicable to the exercise of the subscription rights of newly issued shares of the Company or the acquisition of outstanding shares of the Company, derived from the securities of this nature issued pursuant to the delegation of powers granted. The criteria envisaged in section (v) above shall be applicable to these types of issues, with any necessary adjustments so that they comply with legal and financial provisions regulating such securities.

(vii) Other delegated powers

This authorization to the Board of Directors also includes, without limitation, the delegation to it of the following powers:

- a. the power, pursuant to the provisions of article 511 of the Capital Companies Law, to exclude, in whole or in part, the shareholders' pre-emptive subscription right, in compliance with legal requirements in this regard.

Nevertheless, without prejudice to compliance with any other legal limits established in that regard at any time, the power to exclude pre-emptive subscription rights shall be limited as follows: the nominal amount of the capital increases approved or effectively carried out as part of the conversion of any issues made by virtue of this delegation (without prejudice to any anti-dilution adjustments) excluding the pre-emptive subscription rights and that are resolved or executed also excluding the pre-emptive subscription right by virtue of the delegation given in item nine, above, on the agenda for this Shareholders' Meeting (without prejudice to any anti-dilution adjustments), may not exceed the overall maximum nominal amount of ten percent (10%) of the share capital of Fluidra, S.A. at the time of this delegation.

- b. the power to increase the capital in the amount necessary to meet requests to convert and/or exercise the share subscription right. This power may only be exercised to the extent that the capital increased by the Board of Directors to meet the issue of convertible securities or warrants in question does not exceed the limit not used that is authorized from time to time by the Shareholders' Meeting pursuant to the provisions of article 297.1.b) of the Capital Companies Law, notwithstanding the application of anti-dilution clauses and adjustment of the conversion ratio. This authorization to increase the capital includes the power to issue, on one or more occasions, the shares representing same that are necessary to perform the conversion and/or exercise the share subscription right, and to reword the articles of the Articles of Association relating to the capital stock figure and number of shares, in order to, where applicable, cancel the part of the capital increase that is not necessary for the conversion and/or exercise of the share subscription right;
- c. the power to explain and specify the basis and methods of conversion, exchange and/or exercise of the share subscription and/or acquisition rights

resulting from the securities to be issued, bearing in mind the criteria set forth in sections (v) and (vi) above;

- d. the delegation of powers to the Board of Directors includes the broadest powers necessary in law to interpret, apply, perform and pursue the resolutions to issue convertible or exchangeable securities or warrants, one or several times, and the corresponding capital increase and it is also granted powers to remedy and supplement same as necessary, and also to comply with any legal requirements that may be necessary to ensure their successful outcome, with the ability to remedy any omissions or defects in said resolutions, indicated by any authorities, officials or bodies, Spanish or foreign and it is also authorized to adopt any resolutions and execute any public or private documents that it considers necessary or advisable to bring the preceding resolutions on the issue of convertible or exchangeable securities or warrants and the corresponding capital increase into line with the oral or written assessment of the Commercial Registrar or, in general, any Spanish or foreign competent authorities, officials or institutions.

(viii) Admission to trading

The Company will request, where applicable, the admission to trading on official or unofficial secondary markets, organized or otherwise, Spanish or foreign, of the debentures and/or convertible or exchangeable bonds or warrants issued by the Company by virtue of this delegation, empowering the Board of Directors as broadly as may be necessary in law, to perform the formalities and steps necessary or appropriate for admission to trading before the competent bodies of the different securities markets, Spanish and foreign, subject to the rules on admission, permanence and, where applicable, exclusion from the negotiation.

(ix) Guarantee of issues of convertible and/or exchangeable securities or warrants by subsidiaries

The Board of Directors of the Company shall also be empowered to secure, in the name of the Company, within the above-mentioned limits, new issues of convertible and/or exchangeable securities or warrants that are performed by dependent companies during the period of duration of this resolution.

(x) Power of delegation

To empower the Board of Directors, in the broadest terms, to exercise the delegation made in this resolution, as well as to perform all acts, procedural formalities and requests as may be necessary or advisable for the exercise thereof, authorizing the Board to subdelegate to the Executive Chairman of the Board of Directors, to the Chief Executive Officer or to any other director, and to empower, with the scope deemed necessary, any attorney-in-fact of the Company for its execution.

From the moment of its approval, this authorization supersedes and cancels the authorization granted by the Company's Annual Shareholders' Meeting held on May 5, 2022, under agenda item seventeen.

Item Eleven: **Authorization to the Board of Directors, for a term of 5 years, to issue fixed-income securities and preferred shares up to an amount of €1,800,000,000 and to guarantee issues of those securities made by other companies in its group.**

Approved resolution

To authorize the Board of Directors, in accordance with the general rules on debenture issues and with the provisions of article 319 of the Commercial Registry Regulations, to issue securities in accordance with the following conditions:

(i) Securities issued

The securities to which this authorization refers are fixed-income securities or similar debt instruments in any of the forms admitted by law, both nonconvertible and exchangeable for outstanding shares or other preexisting securities of other companies (including, in particular, debentures, bonds and promissory notes) and preferred shares. The delegation includes the power to establish and/or renew tap or open issue programs for debentures, bonds and other similar fixed-income securities, such as promissory notes, under this or any other name.

(ii) Duration of the delegation

The securities covered by this authorization may be issued once or several times within the maximum term of five years following the date on which this resolution is adopted, at the end of which term the authorization shall be canceled due to expiration with respect to the part not exercised.

(iii) Maximum amount of the delegation

The total maximum amount of the fixed-income securities issue or issues (bonds or simple debentures and other fixed-income securities of a similar nature) other than promissory notes, and preferred shares that are approved pursuant to this authorization, shall be one billion five hundred million euros (€1,500,000,000) or its equivalent in another currency.

For its part, the outstanding nominal balance of promissory notes issued pursuant to this authorization may not exceed at any time three hundred million euros (€300,000,000) or its equivalent in any other currency. This limit is regardless of what is established in the previous section.

(iv) Scope of the authorization

The scope of this authorization extends, as broadly as required by law, to establishing the various aspects and conditions of each issue, including, but not limited to, the par value, issue price, redemption price, currency of the issue, interest rate, subordination clauses, guarantees of the issue, place of the issue, placement and subscription rules, admission to listing, applicable legislation, etc., and, in general, any other condition of the issue, as well as, if applicable, designating the trustee and approving the essential rules that will govern the legal relations between the Company and the syndicate of holders of the securities that are issued, if necessary or a decision is made to set up such syndicate, and to performing such acts and steps as may be necessary, including those established in the securities market legislation, for the execution of the specific issues that may be approved pursuant to this delegation.

The delegation also includes the conferral on the Board of Directors of the power to decide, in each case, on the conditions for redemption of the fixed-income securities issued under this authorization, being able to use, to the extent applicable, the means of redemption referred to in article 430 of the Capital Companies Law or any others that may be applicable. The Board of Directors is also authorized, when it sees fit, and subject to obtaining the necessary authorizations, where applicable, to the formalities established in the respective issues, and to the approval of the Assemblies of the corresponding Syndicates or bodies representing the holders of the securities, if required, to modify the terms and conditions of the fixed-income securities issued in each of the issues made under this authorization.

(v) Admission to trading

The Company will request, where appropriate, the admission to listing on official or non-official secondary markets, organized or otherwise, domestic or foreign, of the securities issued by the Company pursuant to this delegation, authorizing the Board of Directors, as broadly as required by law, to perform such steps and acts as may be necessary for the admission to listing vis-à-vis the competent bodies of the various domestic or foreign securities markets, subject to the rules on admission, permanence and, as the case may be, exclusion from trading.

(vi) Guarantee of securities issued by subsidiaries

The Board of Directors is also authorized to guarantee in the name of the Company, within the above-mentioned limits, the new securities issues made by subsidiaries during the term of this resolution.

(vii) Power of delegation

To empower the Board of Directors, in the broadest terms, to exercise the delegation made in this resolution, as well as to perform all acts, procedural formalities and requests as may be necessary or advisable for the exercise thereof, authorizing the Board to subdelegate to the Executive Chairman of the Board of Directors, to the Chief Executive Officer or to any other director, and to empower, with the scope deemed necessary, any attorney-in-fact of the Company for its execution.

From the moment of its approval, this authorization supersedes and cancels the authorization granted by the Company's Annual Shareholders' Meeting held on May 5, 2022, under agenda item eighteen.

Item Twelve: **Authorization to the Board of Directors, during a 5-year period, so the Company can proceed with the derivative acquisition of treasury shares, directly or through companies in its group. Authorization to reduce the share capital in order to redeem treasury shares, delegating to the Board of Directors the powers necessary to implement this resolution.**

Approved resolution

To authorize the derivative acquisition by Fluidra, S.A., directly or through any of its subsidiaries and during a period of five (5) years from the date this resolution is approved, of treasury shares, at any time and on as many occasions as deemed advisable, through any of the means permitted by law, including with a charge to earnings for the year and/or unrestricted reserves, all in accordance with the provisions of the applicable legislation, as well as to subsequently sell the shares acquired through any means permitted by law.

The derivative acquisition of Company shares shall be subject to the conditions established in the internal or external rules and legislation that, as the case may be, are applicable at any given time, as well as to any limits that may be established by any competent authority. In this regard and in particular, the par value of the treasury shares directly or indirectly acquired in application of this authorization, when added to the par value of the shares already held by the Company and its subsidiaries at any given time, may not exceed, at any time, ten percent (10%) of the subscribed share capital of Fluidra, S.A. (or any other lower limit established by the legislation applicable at any given time).

Furthermore, the derivative acquisition of Company shares shall be subject to the condition that the per-share acquisition price may not be higher than the stock market price or lower than the par value of the shares.

Authorization is expressly given for the shares acquired by the Company or by its subsidiaries in application of this authorization to be used, in part or in full, for delivery to directors or employees of the Company or of its subsidiaries, either directly or as a result of the exercise by such directors or employees of any share options they hold.

From the moment of its approval, this authorization supersedes and cancels the authorization granted by the Company's Annual Shareholders' Meeting held on May 5, 2022, under agenda item nineteen.

To empower the Board of Directors, in the broadest terms, to exercise the authorization made in this resolution, as well as to perform all acts, procedural formalities and requests as may be necessary or advisable for the exercise thereof, authorizing the Board to subdelegate said powers to the Chairman of the Board of Directors, to the Chief Executive

FLUIDRA

Officer or to any other director, and to empower, with the scope deemed necessary, any attorney-in-fact of the Company for its execution.

In addition, the Board of Directors is authorized to reduce the Company's share capital up to a maximum amount corresponding to ten percent (10%) of the share capital on the date of this resolution (that is, up to a maximum nominal amount of NINETEEN MILLION TWO HUNDRED TWELVE THOUSAND NINE HUNDRED AND SEVEN EUROS (€19,212,907.00), corresponding to NINETEEN MILLION TWO HUNDRED TWELVE THOUSAND NINE HUNDRED AND SEVEN (19,212,907) shares with a par value of 1 euro) through the redemption of treasury shares that have been acquired derivatively by the Company under the previous authorization, through any mechanism with the aim of being redeemed, all in accordance with the provisions of the applicable legislation and regulations. The period for implementing this resolution will be five (5) years from the date of approval of this resolution, with any unimplemented portion becoming null and void as from that date.

The definitive figure for the capital reduction may be established by the Board of Directors, within the aforementioned maximum limit, based on the final number of shares acquired and that the Board of Directors decides to redeem pursuant to the delegation of powers approved below.

To empower the Board of Directors, in the broadest terms, authorizing it to subdelegate to the Executive Chairman of the Board of Directors, to the Chief Executive Officer or to any other director, and to any other person that the Board expressly empowers for that purpose, to fully and partially execute the aforementioned approved share capital reduction, on one or more occasions, within the execution period established and in the form it deems most advisable, and may, in particular but without limitation:

- (i) Determine the number of shares to be redeemed in each execution, and may determine to not fully or partially execute the resolution if no acquisition of treasury shares will be ultimately carried out with the purpose of subsequent redemption or if acquisitions were carried out with such purposes, (a) enough shares were not acquired, on one or more occasions, to reach the limit of ten percent (10%) of the share capital on the date of this resolution; or (b) the market conditions, the Company's situation or any other fact with corporate or economic bearing so warrants in the corporate interest or prevents execution; in all cases with this decision being reported at the next Annual Shareholders' Meeting.
- (ii) Declare each one of the capital reduction executions ultimately approved as closed, establishing, as the case may be, the final number of shares to be redeemed and, therefore, the amount by which the Company's share capital is to be reduced in each execution, in accordance with the limits established in this resolution.
- (iii) Give new wording to the article of the Articles of Association that sets the share capital so that it reflects the new share capital figure and the number of outstanding shares following the execution of the capital reduction approved.

- (iv) Request, as the case may be, the delisting of any shares redeemed under this delegation from Spanish or foreign official or unofficial secondary markets, whether regulated or not, and take any action or measures necessary or advisable to that end before the corresponding public and/or private bodies, including any actions, statements or formalities before any competent authorities in any jurisdiction.
- (v) Subscribe any and all public and/or private documents and perform any acts, legal transactions, contracts, statements and operations necessary or advisable to carry out each execution of the capital reduction resolved.
- (vi) Issue any announcements necessary or advisable in connection with the capital reduction and each one of its executions, and carry out all actions necessary for the effective redemption of the shares referred to in this resolution.
- (vii) Establish the terms and conditions for the reduction in all aspects not envisaged in this resolution, and carry out any actions and procedural formalities necessary in order to secure any consents and authorizations required for the effectiveness of this resolution.

Item Thirteen:

Delegation of powers to formalize, interpret, supplement, develop, correct and execute the resolutions adopted by the shareholders' meeting.

Approved resolution

To delegate to the Board of Directors, with express powers of substitution in the Chairman, the Chief Executive Officer and/or the non-director Secretary and Deputy Secretary of the Board so that any of them, indistinctly, may formalize and notarize the resolutions adopted at this Shareholders' Meeting and, in particular, to file at the Commercial Registry, for deposit, the certification of the resolutions approving the annual financial statements and the allocation of profit or loss, and to execute any public or private documents as may be necessary until the relevant entry of the adopted resolutions at the Commercial Registry is obtained, including the request for partial entry, with powers, even, for their correction or rectification in view of the oral or written assessment that may be issued by the Registrar.

Sant Cugat del Vallès, on 6 May 2026